Chemotherapy continues to be a major treatment strategy for various human malignancies. However, the frequent emergence of chemoresistance compromises chemotherapy efficacy leading to poor prognosis. Thus, overcoming drug resistance is pivotal to achieve enhanced therapy efficacy in various cancers. Although increased evidence has revealed that reduced drug uptake, increased drug efflux, drug target protein alterations, drug sequestration in organelles, enhanced drug metabolism, impaired DNA repair systems, and anti-apoptotic mechanisms, are critically involved in drug resistance, the detailed resistance mechanisms have not been fully elucidated in distinct cancers. Recently, F-box protein (FBPs), key subunits in Skp1-Cullin1-F-box protein (SCF) E3 ligase complexes, have been found to play critical roles in carcinogenesis, tumor progression, and drug resistance through degradation of their downstream substrates. Therefore, in this review, we describe the functions of FBPs that are involved in drug resistance and discuss how FBPs contribute to the development of cancer drug resistance. Furthermore, we propose that targeting FBPs might be a promising strategy to overcome drug resistance and achieve better treatment outcome in cancer patients. Lastly, we state the limitations and challenges of using FBPs to overcome chemotherapeutic drug resistance in various cancers.

化学疗法仍然是各种人类恶性肿瘤的主要治疗策略。然而，化学抗性的频繁出现损害了化学疗法的效力，导致不良的预后。因此，克服耐药性对于在各种癌症中实现增强的治疗功效至关重要。尽管越来越多的证据表明，减少的药物吸收，增加的药物外排，药物靶蛋白的变化，细胞器中的药物隔离，增强的药物代谢，受损的DNA修复系统和抗凋亡机制，都与耐药性密切相关，详细的耐药机制在不同的癌症中尚未完全阐明。最近，发现F-box蛋白（FBP）是Skp1-Cullin1-F-box蛋白（SCF）E3连接酶复合物的关键亚基，在癌变，肿瘤进展，通过其下游底物的降解而产生耐药性。因此，在这篇综述中，我们描述了参与耐药性的FBP的功能，并讨论了FBP如何促进癌症耐药性的发展。此外，我们建议靶向FBP可能是克服耐药性并在癌症患者中获得更好治疗效果的一种有前途的策略。最后，我们陈述了在各种癌症中使用FBP克服化疗药物耐药性的局限性和挑战。我们建议针对FBPs可能是克服癌症患者耐药性并获得更好治疗结果的一种有前途的策略。最后，我们陈述了在各种癌症中使用FBP克服化疗药物耐药性的局限性和挑战。我们建议针对FBPs可能是克服癌症患者耐药性并获得更好治疗结果的一种有前途的策略。最后，我们陈述了在各种癌症中使用FBP克服化疗药物耐药性的局限性和挑战。